Join our community of smart investors

Fightback

Finding a cure – or vaccine – for Covid-19 is a matter of global urgency. Megan Boxall and Dave Baxter find out who’s leading the charge, what the risks are for investors, and how the virus could change the delivery of healthcare forever
March 19, 2020 and Dave Baxter

In the week since we published our overview of the healthcare industry’s counter attack on Covid-19, the situation has escalated rapidly - cases have accelerated and global governments have taken a tougher stance. Meanwhile, scientists' understanding of the disease continues to expand, giving pharma companies more ammunition as they mount a fightback.

We have therefore decided to update our overview of the situation, in an article which you can read here. 

On 31 December 2019, scientists identified a strain of virus that had never been seen in humans before. The months that followed this discovery have been dominated by images of an approaching apocalypse: empty streets in some of the world’s biggest cities, stranded cruise-ships, supermarket shelves swept of essential items and long-life goods, and strictly enforced fines for breaking curfew in locked-down cities.

Coronavirus has come to dominate news cycles, social media and conversation. It has informed economic decisions, including the biggest interest rate cut in the US since the 2008 financial crisis. It is, inevitably, starting to be used as a political tool. But ultimately this is a human health issue, one that is not being helped by political distractions and mass hysteria.

To continue reading...
REGISTER FOR FREE TODAY
  • Read 3 articles for free each month
  • Educational articles and topical investment guides
  • In-depth podcast episodes by our writers and industry professionals
  • Interactive live webinars on investment themes that matter
Have an account? Sign in